Matches in Wikidata for { <http://www.wikidata.org/entity/Q95854250> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- Q95854250 description "article scientifique publié en 2020" @default.
- Q95854250 description "artículu científicu espublizáu en mayu de 2020" @default.
- Q95854250 description "scientific article published on 27 May 2020" @default.
- Q95854250 description "wetenschappelijk artikel" @default.
- Q95854250 description "наукова стаття, опублікована 27 травня 2020" @default.
- Q95854250 name "Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer" @default.
- Q95854250 name "Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer" @default.
- Q95854250 type Item @default.
- Q95854250 label "Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer" @default.
- Q95854250 label "Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer" @default.
- Q95854250 prefLabel "Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer" @default.
- Q95854250 prefLabel "Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer" @default.
- Q95854250 P1433 Q95854250-311B0CA9-F07E-41B4-8CA9-29CAB28C7E3E @default.
- Q95854250 P1476 Q95854250-1A63A3A7-1039-48F6-90C6-D376329534EF @default.
- Q95854250 P2093 Q95854250-1180680A-A113-419A-903C-320CD9291ED3 @default.
- Q95854250 P2093 Q95854250-22C9FCBC-79A6-4D7E-AF91-FE45AE8274F2 @default.
- Q95854250 P2093 Q95854250-236DAE20-CBED-4A99-9DA7-A87A38576389 @default.
- Q95854250 P2093 Q95854250-2A093E82-604A-4E4F-A521-A456341E4079 @default.
- Q95854250 P2093 Q95854250-2BD4F0BD-8A9D-42BB-B19C-F9C4AAA5B89D @default.
- Q95854250 P2093 Q95854250-2E520378-75A8-4BE5-9695-82058FB19F48 @default.
- Q95854250 P2093 Q95854250-39067EE7-52FA-43C6-B48D-EB310140F92C @default.
- Q95854250 P2093 Q95854250-3A5C6D5E-4F8C-4B38-89A6-1CC09C5E8912 @default.
- Q95854250 P2093 Q95854250-3D92405F-7ED7-44D3-8307-0642A594C616 @default.
- Q95854250 P2093 Q95854250-45277B49-81A4-41A4-950E-360DB0FF61B1 @default.
- Q95854250 P2093 Q95854250-49C815B7-82B6-47FC-B8BF-0A7E164FAE75 @default.
- Q95854250 P2093 Q95854250-7220E58C-E722-4D2F-B7EC-2E0E4E4B993D @default.
- Q95854250 P2093 Q95854250-78BA212D-7412-4C12-9B6D-B7819C20ACDA @default.
- Q95854250 P2093 Q95854250-93FEA24C-B17D-4339-9CAD-FD929F79BD52 @default.
- Q95854250 P2093 Q95854250-C03DE992-AF17-4DC7-9411-6D5EC6433469 @default.
- Q95854250 P2093 Q95854250-CD2D0A98-03F2-4C3E-951D-53F654ECC829 @default.
- Q95854250 P2093 Q95854250-DE263F46-644D-4663-96F0-8F78E4579154 @default.
- Q95854250 P2093 Q95854250-F4F3DFE2-53ED-4582-A104-6D826CF913EB @default.
- Q95854250 P2093 Q95854250-F897A6F1-7FA9-4979-BB0A-D2EB90878C3D @default.
- Q95854250 P304 Q95854250-7E87D768-4805-4722-901C-B1D2F76BFE10 @default.
- Q95854250 P31 Q95854250-D076DB45-4441-4255-8F89-13374F13667D @default.
- Q95854250 P356 Q95854250-D976655E-122C-4A8B-9F1B-367B76C7F0F9 @default.
- Q95854250 P577 Q95854250-98E4BC8A-8C98-4174-8175-77261F611081 @default.
- Q95854250 P698 Q95854250-47212658-5AC5-4697-9EAF-F189EF203B21 @default.
- Q95854250 P921 Q95854250-29923DF1-7747-4EDD-A741-E00B14418EF2 @default.
- Q95854250 P921 Q95854250-BBB98FD6-E6A0-461A-87A4-9D7311B8A898 @default.
- Q95854250 P932 Q95854250-6DC3A3F5-7960-4E48-8A40-62DA7F82A2C9 @default.
- Q95854250 P356 JCO.19.03158 @default.
- Q95854250 P698 32459597 @default.
- Q95854250 P1433 Q400292 @default.
- Q95854250 P1476 "Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer" @default.
- Q95854250 P2093 "Anthony Lee" @default.
- Q95854250 P2093 "Carlo Barone" @default.
- Q95854250 P2093 "Claudia Kelsch" @default.
- Q95854250 P2093 "Denis Moro-Sibilot" @default.
- Q95854250 P2093 "Elisabeth Piault" @default.
- Q95854250 P2093 "Francisco Orlandi" @default.
- Q95854250 P2093 "Geetha Shankar" @default.
- Q95854250 P2093 "Hina Patel" @default.
- Q95854250 P2093 "Jeffrey Rothenstein" @default.
- Q95854250 P2093 "Jose Luis González Larriba" @default.
- Q95854250 P2093 "Mark A Socinski" @default.
- Q95854250 P2093 "Martin Früh" @default.
- Q95854250 P2093 "Martin Reck" @default.
- Q95854250 P2093 "Mikhail Shtivelband" @default.
- Q95854250 P2093 "Naoyuki Nogami" @default.
- Q95854250 P2093 "Shelley Coleman" @default.
- Q95854250 P2093 "Thomas Wehler" @default.
- Q95854250 P2093 "Wei Yu" @default.
- Q95854250 P2093 "Yu Deng" @default.
- Q95854250 P304 "JCO1903158" @default.
- Q95854250 P31 Q13442814 @default.
- Q95854250 P356 "10.1200/JCO.19.03158" @default.
- Q95854250 P577 "2020-05-27T00:00:00Z" @default.
- Q95854250 P698 "32459597" @default.
- Q95854250 P921 Q413299 @default.
- Q95854250 P921 Q974135 @default.
- Q95854250 P932 "7392741" @default.